Results 161 to 170 of about 2,626 (203)
Some of the next articles are maybe not open access.
Tralokinumab in Atopic Dermatitis: A Profile of Its Use
Clinical Drug Investigation, 2022Tralokinumab (tralokinumab-ldrm) [Adbry™ (USA); Adtralza® (EU)], a human IgG4 monoclonal antibody that binds specifically to interleukin (IL)-13, is an effective and generally well tolerated treatment option for adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.
openaire +2 more sources
Tralokinumab‐related facial redness: a therapeutic challenge
International Journal of DermatologyAtopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczematous lesions, and lichenification. Treating patients with severe forms of AD is generally challenging for dermatologists. Here, we describe a case of tralokinumab-related facial redness in a patient who had a good response to the drug previously.
Sergio García‐González +4 more
openaire +4 more sources
Tralokinumab for the treatment of atopic dermatitis
Prescriber, 2022Tralokinumab (Adtralza) is a new anti‐IL‐13 monoclonal antibody for the treatment of moderate to severe atopic dermatitis. This article summarises its administration, clinical trial efficacy and adverse effects.
openaire +1 more source
Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab
Australasian Journal of DermatologyAbstractDyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects ...
Nisha V. Parmar, Anwar Al Hammadi
openaire +2 more sources
Corneal Perforation Associated With Tralokinumab
CorneaPurpose: The purpose of this study was to report the first documented case of peripheral corneal perforation associated with tralokinumab therapy for atopic dermatitis. Methods: A detailed clinical examination, imaging, and comprehensive systemic workup were performed to determine ...
Javier García-Bardera +6 more
openaire +1 more source
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
European Respiratory Journal, 2019Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists ...
Busse, William +9 more
openaire +3 more sources
Tralokinumab in elderly atopic dermatitis
Italian Journal of Dermatology and Venereology, 2023Napolitano, Maddalena +5 more
openaire +3 more sources
Clinical and economic evaluation of tralokinumab for atopic dermatitis
Journal of Managed Care & Specialty PharmacyTralokinumab is the first selective interleukin 13 inhibitor approved for moderate to severe atopic dermatitis. This article reports the findings of a comprehensive literature review and extensive economic analysis to assess tralokinumab's safety, effectiveness, and cost.
Ryan A, Moreau +4 more
openaire +2 more sources
Tralokinumab treatment in atopic dermatitis: Depicting super‐responders
The Journal of Dermatology, 2023Alberto Alegre‐Bailo +4 more
openaire +2 more sources